Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of TRK-950 in Advanced Solid Tumors and Melanoma
jRCT2031220130Phase 2Recruiting
- Sponsor
- Toray Industries
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TRK-950 in Nonhematologic neoplasms and melanoma (4 arms), sponsored by Toray Industries. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs), Number of participants with adverse events (AEs) and 3 more. Started Jul 2022; status: recruiting.
02
Drugs
TRK-950
03
Conditions
Nonhematologic neoplasmsmelanoma
Beyond the preview
Go deeper on jRCT2031220130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220130.